Financhill
Buy
53

SBMFF Quote, Financials, Valuation and Earnings

Last price:
$0.87
Seasonality move :
-3.14%
Day range:
$0.87 - $0.87
52-week range:
$0.37 - $1.24
Dividend yield:
1.32%
P/E ratio:
30.49x
P/S ratio:
3.70x
P/B ratio:
4.10x
Volume:
--
Avg. volume:
162
1-year change:
92.09%
Market cap:
$15.6B
Revenue:
$4B
EPS (TTM):
$0.03

Analysts' Opinion

  • Consensus Rating
    No consensus rating exists at this time due to lack of analyst coverage.
  • Price Target Downside
    No price target exists because of limited analyst coverage.
  • Price Target Upside
    Similarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.

Fair Value

  • According to the consensus of 0 analysts, Sino Biopharmaceutical Ltd. has -- downside to fair value with a price target of -- per share.

SBMFF vs. S&P 500

  • Over the past 5 trading days, Sino Biopharmaceutical Ltd. has underperformed the S&P 500 by -0.12% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • Sino Biopharmaceutical Ltd. does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Sino Biopharmaceutical Ltd. has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Sino Biopharmaceutical Ltd. reported revenues of --.

Earnings Growth

  • Sino Biopharmaceutical Ltd. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Sino Biopharmaceutical Ltd. reported earnings per share of --.
Enterprise value:
17.1B
EV / Invested capital:
--
Price / LTM sales:
3.70x
EV / EBIT:
19.41x
EV / Revenue:
4.04x
PEG ratio (5yr expected):
0.31x
EV / Free cash flow:
15.54x
Price / Operating cash flow:
14.24x
Enterprise value / EBITDA:
16.00x
Gross Profit (TTM):
$3.5B
Return On Assets:
5.38%
Net Income Margin (TTM):
22.11%
Return On Equity:
8.57%
Return On Invested Capital:
6.83%
Operating Margin:
--
Trailing 12 Months Fiscal Quarters
Period Ending 2019-06-30 2020-06-30 2021-06-30 2020-06-30 2021-06-30
Income Statement
Revenue $3.5B $3.5B $2.4B $906.2M $1.1B
Gross Profit -- -- -- $691.1M $893.5M
Operating Income -- -- -- $203.7M $276.9M
EBITDA -- -- -- $197.6M $1.3B
Diluted EPS -- -- -- $0.00 $0.05
Period Ending 2021-06-30 2022-06-30 2023-06-30 2024-06-30 2025-06-30
Balance Sheet
Current Assets $3.7B $3.8B $3.7B $3.5B --
Total Assets $8.7B $9.7B $9B $9.2B --
Current Liabilities $1.8B $2.4B $3.7B $3B --
Total Liabilities $3.9B $3.9B $4B $3.4B --
Total Equity $4.8B $5.8B $5B $5.8B --
Total Debt -- -- -- -- --
Trailing 12 Months Fiscal Quarters
Period Ending 2019-06-30 2020-06-30 2021-06-30 2020-06-30 2021-06-30
Cash Flow Statement
Cash Flow Operations -- -- $405.3M $219.4M $361.5M
Cash From Investing -- -- -- -$216.3M -$627.7M
Cash From Financing -- -- -- $720.7M -$117.9M
Free Cash Flow -- -- -- -- --
SBMFF
Sector
Market Cap
$15.6B
$28.8M
Price % of 52-Week High
70.33%
51.13%
Dividend Yield
1.32%
0%
Shareholder Yield
2.26%
-1.32%
1-Year Price Total Return
92.09%
-20.64%
Beta (5-Year)
0.715
0.520
Dividend yield:
1.32%
Annualized payout:
$0.01
Payout ratio:
-27.49%
Growth streak:
0 years

Technicals

8-day SMA
Sell
Level $0.87
200-day SMA
Buy
Level $0.73
Bollinger Bands (100)
Sell
Level 0.85 - 1.07
Chaikin Money Flow
Sell
Level -1.6K
20-day SMA
Sell
Level $0.87
Relative Strength Index (RSI14)
Sell
Level 33.23
ADX Line
Sell
Level 31
Williams %R
Sell
Level 0
50-day SMA
Sell
Level $0.92
MACD (12, 26)
Sell
Level -0.01
25-day Aroon Oscillator
Buy
Level 76
On Balance Volume
Sell
Level -7.8K

Financial Scores

Hold
Altman Z-Score (Annual)
Level (2.8631)
Buy
CA Score (Annual)
Level (0.0701)
Buy
Beneish M-Score (Annual)
Level (-2.5113)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (-2.0107)
Buy
Piotroski F Score (Annual)
Level (9)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Sino Biopharmaceutical Ltd. is an investment holding company, which engages in the manufacture and sale of pharmaceutical products. It operates through the following business segments: Investment, Modernised Chinese Medicines and Chemical Medicines; and Others. The Investment segment offers long-term investments. The Modernised Chinese Medicines and Chemical Medicines segment comprises the manufacturing, selling, and distribution of modernized Chinese medicine products and western medicine products. The Investment segment offers long-term investments. The Other segment includes a research and development sector, which provides services to third parties; and related healthcare and hospital business. It also develops medicines for treating tumors, analgesia, diabetes, and respiratory system diseases. The company was founded by Ping Tse Cheung Ling Cheng and on February 2, 2000, and is headquartered in Hong Kong.

Stock Forecast FAQ

In the current month, SBMFF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The SBMFF average analyst price target in the past 3 months is --.

  • Where Will Sino Biopharmaceutical Ltd. Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Sino Biopharmaceutical Ltd. share price will drop to -- per share over the next 12 months.

  • What Do Analysts Say About Sino Biopharmaceutical Ltd.?

    Analysts are divided on their view about Sino Biopharmaceutical Ltd. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Sino Biopharmaceutical Ltd. is a Sell and believe this share price will rise from its current level to --.

  • What Is Sino Biopharmaceutical Ltd.'s Price Target?

    The price target for Sino Biopharmaceutical Ltd. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.

  • Is SBMFF A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Sino Biopharmaceutical Ltd. is a --. 0 of 0 analysts rate the stock a -- at this time.

  • How Can I Buy Shares Of SBMFF?

    You can purchase shares of Sino Biopharmaceutical Ltd. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Sino Biopharmaceutical Ltd. shares.

  • What Is The Sino Biopharmaceutical Ltd. Share Price Today?

    Sino Biopharmaceutical Ltd. was last trading at $0.87 per share. This represents the most recent stock quote for Sino Biopharmaceutical Ltd.. Yesterday, Sino Biopharmaceutical Ltd. closed at $0.87 per share.

  • How To Buy Sino Biopharmaceutical Ltd. Stock Online?

    In order to purchase Sino Biopharmaceutical Ltd. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Amazon an AI Stock?
Is Amazon an AI Stock?

With the market starting to look skittish on pure-play AI…

Google Vs NVIDIA Stock: Which Is Best?
Google Vs NVIDIA Stock: Which Is Best?

Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…

How High Could NVIDIA Stock Go?
How High Could NVIDIA Stock Go?

NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…

Stock Ideas

Buy
52
Is NVDA Stock a Buy?

Market Cap: $4.5T
P/E Ratio: 62x

Buy
61
Is AAPL Stock a Buy?

Market Cap: $4.1T
P/E Ratio: 38x

Buy
63
Is GOOG Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 40x

Alerts

Buy
54
SMX alert for Dec 5

SMX (Security Matters) Plc [SMX] is up 222.7% over the past day.

Sell
15
HOV alert for Dec 5

Hovnanian Enterprises, Inc. [HOV] is up 1.39% over the past day.

Buy
67
NUTX alert for Dec 5

Nutex Health, Inc. [NUTX] is up 2.34% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock